BOSTON, Mass. ( TheStreet) -- A calendar of important, potentially stock-moving biotech events for November:

Nov. 2
Dendreon ( DNDN) third-quarter earnings. Will Provenge sales recover?

Nov. 3-5
North American Cystic Fibrosis Conference: Vertex Pharmaceuticals ( VRTX) presenting Kalydeco data.

Nov. 4-8
American Association for the Study of Liver Disease (AASLD) annual meeting. Key presentations of hepatitis C drug data from Pharmasset ( VRUS), Bristol-Myers Squibb ( BMY), Vertex Pharmaceuticals, Merck ( MRK), Johnson & Johnson ( JNJ) and others.

Nov. 5-9
American College of Rheumatology (ACR) annual meeting.

Nov. 7
Roche ( RHHBY) analyst/investor meeting.
American Society of Hematology (ASH) annual meeting research abstracts released: Ariad Pharmaceuticals ( ARIA), Celgene ( CELG), YM BioSciences ( YMI).

Nov. 10
Merck analyst/investor meeting.

Nov. 11
FDA approval decision for Alimera Sciences ( ALIM) and pSivida's ( PSDV) Iluvien for diabetic macular edema.

Nov. 12-16
American Heart Association Scientific Sessions: Aastrom Biosciences ( ASTM), Amarin ( AMRN).
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.

Nov. 13
FDA approval decision for IntelGenx's ( IGXT.OB) CPI-300 anti-depressant.

Nov. 16
FDA advisory panel convened to review Salix Pharmaceuticals' ( SLXP) Xifaxan for irritable bowel syndrome with diarrhea.

Nov. 18
FDA approval decision for Regeneron Pharmaceuticals' ( REGN) Eyelea for age-related macular degeneration.

Nov. 27
FDA approval decision for Transcept Pharmaceuticals' ( TSPT) Intermezzo sleeping pill.

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein.

>To submit a news tip, send an email to: tips@thestreet.com.

Follow TheStreet on Twitter and become a fan on Facebook.
Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.